Proportion of susceptible participants who did not experience any motion sickness symptoms under experimental conditions Assessed by: calculated based on head movements tolerated (rotating chair); MSAQ · patients with motion sickness
1 finding from 1 review
Proportion of susceptible participants who experienced a reduction or resolution of existing motion sickness symptoms · patients with motion sickness
The review found no eligible studies for this question.
1 finding from 1 review
Physiological measures: heart rate and core temperature · patients with motion sickness
The review found no eligible studies for this question.
1 finding from 1 review
Physiological measures: gastric tachyarrhythmia10 Assessed by: electrogastrography · patients with motion sickness
1 finding from 1 review
Adverse effects: 1. Sedation · patients with motion sickness
Antihistamines may leads to higher adverse effects: sedation Assessed by: adverse effect questionnaire… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: impaired cognition Assessed by: adverse effect questionnaire (presence or absence given numerical values) · patients with motion sickness
Antihistamines showed no clear difference in adverse effects: impaired cognition Assessed by: adverse effect… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects ‐ Blurred vision No of patients with blurred vision · patients with motion sickness
Antihistamines showed no clear difference in adverse effects: blurred vision Assessed by: adverse effect… compared with placebo (low certainty).
1 finding from 1 review
Days missed from work or school · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
ADHD symptoms · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
3 findings from 1 review
no estimate extracted
16 studies · 3799 participants
Very low
no estimate extracted
18 studies · 4183 participants
Very low
no estimate extracted
3 studies · 1005 participants
Very low
Serious adverse events Median · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
Quality of life, self‐rated at post‐treatment · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
Proportion of participants experiencing adverse events · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
1 finding from 1 review
BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with borderline personality disorder
1 finding from 1 review
Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Interpersonal problems Timing of outcome assessment: end of treatment (32 days to 24 weeks) · patients with borderline personality disorder
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
Antidepressants may leads to higher attrition Timing of outcome assessment: end of treatment (5 weeks to… compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Self‐harm Measured by: clinicians Timing of outcome assessment: end of treatment · patients with borderline personality disorder
It is very uncertain whether mood stabilisers changes self‐harm Timing of outcome assessment: end of treatment (52 weeks… compared with placebo (very low certainty).
1 finding from 1 review